JNJ-61186372, Erbitux 5 mg/mL solution for infusion, Erbitux 5 mg/mL solution for infusion
61186372COR3001
Phase 3 small_molecule active
Quick answer
JNJ-61186372, Erbitux 5 mg/mL solution for infusion, Erbitux 5 mg/mL solution for infusion for KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active